NCT03716076 (CaRDIO) is a Phase 4 clinical trial of Carbetocin in Cardiac Arrythmias, sponsored by University of British Columbia.

Who is sponsoring NCT03716076?

NCT03716076 is sponsored by University of British Columbia.

What drugs are being tested in NCT03716076?

Interventions in NCT03716076: Carbetocin.

What condition does NCT03716076 study?

NCT03716076 studies Cardiac Arrythmias.

Is NCT03716076 still recruiting?

NCT03716076 is currently completed. Last updated 14 May 2021.

Are results published for NCT03716076?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-05-14 · How we verify

NCT03716076: CaRDIO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study

Completed Phase 4 Results posted Last updated 14 May 2021

What this trial tests

Phase 4 trial testing Carbetocin in Cardiac Arrythmias in 50 participants. Completed in 24 April 2020.

Timeline

1 November 2018

Primary endpoint
15 June 2019

24 April 2020

Quick facts

Lead sponsor	University of British Columbia
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	diagnostic
Enrollment	50
Start date	1 November 2018
Primary completion	15 June 2019
Estimated completion	24 April 2020
Sites	1 location across Canada

Drugs / interventions tested

Carbetocin (CARBETOCIN) — full drug profile →

Conditions studied

Cardiac Arrythmias — all drugs for Cardiac Arrythmias →

Sponsor

University of British Columbia

Who can join

19 and older, female only, with Cardiac Arrythmias. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Tp-e Primary · 5 minutes post-carbetocin administration

Time interval between peak and end of T-wave (Tp-e)

Group	Value	95% CI
Participant Receives 50 mcg of Carbetocin Post-delivery.	69.5	± 7.7
Participant Receives 100 mcg of Carbetocin Post-delivery.	74.7	± 4.7

Arrhythmia Secondary · perioperatively, typically ranging 30 minutes-1 hour

Occurrence of Atrial or Ventricular Arrhythmias

Group	Value	95% CI
Participant Receives 50 mcg of Carbetocin Post-delivery.	0
Participant Receives 100 mcg of Carbetocin Post-delivery.	0

QTc at 5 Min Secondary · 5 min post-carbetocin administration

Bazette corrected Q-T interval

Group	Value	95% CI
Participant Receives 50 mcg of Carbetocin Post-delivery.	435.1	± 18.3
Participant Receives 100 mcg of Carbetocin Post-delivery.	434.2	± 18.8

QTc 10 Min Secondary · 10 minutes post-carbetocin administration

Bazette corrected Q-T interval (QTc)

Group	Value	95% CI
Participant Receives 50 mcg of Carbetocin Post-delivery.	431.6	± 18.2
Participant Receives 100 mcg of Carbetocin Post-delivery.	431.9	± 15.4

QTc 5 Min Spinal Secondary · 5 min post-administration of spinal anesthesia

Bazette corrected Q-T interval change after spinal anesthesia

Group	Value	95% CI
Participant Receives 50 mcg of Carbetocin Post-delivery.	409.4	± 19.2
Participant Receives 100 mcg of Carbetocin Post-delivery.	413.6	± 17.4

Tp-e 5 Min Post-spinal Secondary · 5 minutes after administration of spinal anesthesia

Time between peak and end of T-wave,

Group	Value	95% CI
Participant Receives 50 mcg of Carbetocin Post-delivery.	69.5	± 8.6
Participant Receives 100 mcg of Carbetocin Post-delivery.	70.9	± 6.5

Tp-e at 10 Min Secondary · 10 minutes post-carbetocin administration

Time between peak and end of T-wave

Group	Value	95% CI
Participant Receives 50 mcg of Carbetocin Post-delivery.	69.4	± 8.2
Participant Receives 100 mcg of Carbetocin Post-delivery.	71.8	± 5.5

Sponsor's own description

Relationship between carbetocin dose on transmural dispersion of repolarization (TDR).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Carbetocin

Trials testing the same drug.

NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
NCT06946589 — Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section · Phase 4 · not yet recruiting
NCT06776926 — Timing of Carbetocin Administration in Postpartum Hemorrhage · NA · completed
NCT06692621 — Effects of Carbetocin and Oxytocin Used in Cesarean Sections on Postoperative Pain · completed
NCT07380529 — Comparison of the Effect of Carbetocin Versus Oxytocin in the Prevention of Postpartum Hemorrhage After Emergency Caesar · NA · completed

Other recruiting trials for Cardiac Arrythmias

Currently open trials in the same condition.

NCT07361445 — Agilis RF TSP Early Feasibility Study · NA · recruiting
NCT03444259 — Prospective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients · active not recruiting

Other University of British Columbia trials

Trials by the same sponsor.

NCT07340970 — Sensory Stimuli During Cesarean Delivery · not yet recruiting
NCT07481201 — Phenylalanine Requirements in the Menstrual Phases · NA · not yet recruiting
NCT07492095 — Leucine Requirements in School-Age Children · NA · not yet recruiting
NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03716076 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
Last refreshed: 14 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03716076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing